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Abstract
Objective
The microbiome has been implicated in the pathogenesis of a number of allergic and inflam-
matory diseases. The mucosa affected by eosinophilic esophagitis (EoE) is composed of a
stratified squamous epithelia and contains intraepithelial eosinophils. To date, no studies
have identified the esophageal microbiome in patients with EoE or the impact of treatment
on these organisms. The aim of this study was to identify the esophageal microbiome in
EoE and determine whether treatments change this profile. We hypothesized that clinically
relevant alterations in bacterial populations are present in different forms of esophagitis.
Design
In this prospective study, secretions from the esophageal mucosa were collected from chil-
dren and adults with EoE, Gastroesophageal Reflux Disease (GERD) and normal mucosa
using the Esophageal String Test (EST). Bacterial load was determined using quantitative
PCR. Bacterial communities, determined by 16S rRNA gene amplification and 454 pyrose-
quencing, were compared between health and disease.
Results
Samples from a total of 70 children and adult subjects were examined. Bacterial load was
increased in both EoE and GERD relative to normal subjects. In subjects with EoE, load
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was increased regardless of treatment status or degree of mucosal eosinophilia compared
with normal. Haemophilus was significantly increased in untreated EoE subjects as com-
pared with normal subjects. Streptococcus was decreased in GERD subjects on proton
pump inhibition as compared with normal subjects.
Conclusions
Diseases associated with mucosal eosinophilia are characterized by a different microbiome
from that found in the normal mucosa. Microbiota may contribute to esophageal inflamma-
tion in EoE and GERD.
Introduction
The increasing use of culture independent techniques has provided a wealth of information
documenting changes in the microbiome during health and disease. The microbiome associat-
ed with mucosal surfaces has clearly emerged as an important participant in initiating or per-
petuating inflammatory states. In addition, a number of factors, including medications and
nutrition, may contribute to the load and composition of the intestinal microbiome.
Over the last decade, increasing clinical recognition of eosinophilic esophagitis (EoE)
sparked a number of studies examining it pathogenesis. While these studies have identified a
number of genes, pathogenetic pathways and co-morbid features, several factors provide a
framework for considering a primary or secondary role of an altered microbiome in EoE. For
example, basal zone hyperplasia in response to IL-13 may contribute to decreased mucosal bar-
rier function as a primary factor [1], whereas esophageal eosinophils may alter the host micro-
environment and perpetuate the disease and thus contribute as a secondary factor. Eosinophils
are potent reservoirs of a number of anti-microbial products including granule cationic pro-
teins, defensins and DNA-containing extracellular traps (EETs) [2–4]; release of these products
may change the microbiome. Eosinophilic inflammation can disrupt esophageal motility, thus
leading to stasis and proliferation of damaging species. Finally, patients with EoE restrict their
diets due to food allergies, thus potentially changing the substrate for the esophageal bacteria.
On the basis of these findings, we sought to identify the esophageal microbiota in children
and adults with active and inactive EoE. Identification of these microbial communities may
provide clues regarding novel pathogenetic mechanisms and therapeutic targets. We hypothe-
sized that the esophageal microbiota in the mucosa of EoE subjects was different from those
with GERD and normal mucosa. Our findings support a potential role for altered microbiome
in EoE with the affected mucosa harboring more Haemophilus compared to subjects with
GERD or a normal mucosa.
Materials and Methods
Capture of Esophageal microbiome using the Esophageal String Test
(EST)
Children and adults who were undergoing an endoscopy with biopsy to determine causes of
abdominal pain, vomiting, growth failure, dysphagia or histological efficacy of EoE treatment
were enrolled in this study of children and adults from Lurie Children’s Hospital/Stroger Hos-
pital (Chicago) and Children’s Hospital Colorado (Aurora) and Northwestern Hospital (Chi-
cago). Exclusion criteria included age less than 7 years, a history of esophageal stricture or
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narrowing, gelatin allergy or other co-morbidities with increased risk (bleeding diatheses, con-
nective tissue diseases) of endoscopic complications. We included children 7 years and older
because of their ability to swallow a capsule. Histories were taken to record symptoms, allergic
history, family history and medications. Review of endoscopic and pathology records were per-
formed to ensure diagnostic accuracy and determine clinical features [5, 6].
Subject diagnoses were assigned according to the following criteria based on published con-
sensus recommendations [7–9]: (i). Eosinophilic esophagitis (EoE-active)—subjects with
symptoms of esophageal dysfunction, esophageal eosinophilia15 eosinophils per high power
field; (ii). EoE-remission—subjects diagnosed with EoE as defined above who have undergone
at least 8 weeks of treatment (topical steroids or dietary elimination) and who, at the time of
their endoscopy, were both asymptomatic and showed evidence of histologic remission in
terms of decreased esophageal eosinophil counts<15 eos/hpf. The subjects were not proton
pump inhibitor-responsive esophageal eosinophilia PPI-REE. EoE is a male dominated disease,
more than 70% of our EoE subjects were male (iii). GERD—subjects with symptoms of vomit-
ing or heartburn that had responded to proton pump inhibitors (PPI) and/or had an abnormal
pH impedance monitor of the distal esophagus. Subjects in remission were on PPI treatment at
the time of the endoscopy; (iv). Normal—subjects with symptoms that lead to endoscopic test-
ing (abdominal pain, vomiting, growth failure) and who were found to have endoscopically
and histopathologically normal esophagus. Subjects in this study were not on antibiotic treat-
ment. The night before their upper endoscopic procedure, subjects swallowed the Enterotest™
and underwent endoscopy with biopsy the following day as described previously, the EST for
the microbiome identification was collected in the same mid to distal section of the esophagus
as the biopsy in our previously published work [5, 6].
This study was approved by the Colorado Multiple Institutional Review Board (COMIRB),
Aurora, CO, and the IRBs of the University of Illinois at Chicago, Northwestern University
and Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL. Written informed
consent and HIPPA authorization were obtained from all participants or from parents or legal
guardians of participants younger than 18 years. Assent was obtained from all participants
under 18 years.
Microbiota identification
Immediately preceding endoscopy, the EST was removed as described previously [5, 6]. A 2 cm
segment of the middle esophagus was collected and snap frozen in liquid nitrogen and kept at
-80°C until DNA extraction was performed. DNA from all samples was extracted using Qiagen
DNAeasy Extraction Kits for blood and tissue according to manufacturer’s specifications (Qia-
gen, Valencia, CA). DNA was amplified in triplicate with barcoded PCR primers targeting V1/
V2 (27F/338R) [10] that include sequencing adaptors, and negative controls were performed
for each barcode. PCR was repeated for any sample where the negative control was positive.
Amplicons were pooled after normalization of DNA concentration (SequalPrep, Invitrogen)
[11], and sequenced using the Roche 454 FLX platform according to manufacturer’s specifica-
tions (Roche, Branford, CT) with an average of 695 sequences (range 112–2555), with Good's
coverage of>94%. Sequence data were assigned to samples of origin using bar code sequences
added during PCR, and screened for basic quality defects (sequences< 200 nucleotides in
length,> 1 sequence ambiguity, best read with quality 20 over a 10-nucleotide moving win-
dow) by the program BARTAB [12]. Non-bacterial sequences were removed from datasets by
requiring a close match with a bacterial rRNA secondary structure model within Infernal [13].
Sequences identified as potential chimeras by ChimeraSlayer [14] were also removed from
datasets. The Ribosomal Database Project Classifier software was used to make taxonomic
Microbiome Shift in Esophagitis
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assignments [15]. Taxonomic information was used to construct sequence groups with identi-
cal taxonomic rank, which were used for bacterial community analyses, and to identify specific
types of bacteria that were differentially present between subject groups. Sequence counts were
converted to relative abundance to account for differences in sequence totals between samples
[16]. Sequence data has been submitted to NCBI under the accession SRP041586. Total bacteri-
al load was estimated using quantitative PCR (qPCR) with pan-bacterial primers that target the
small subunit ribosomal RNA (SSU-rRNA) as previously described [17, 18]. Bacterial load was
expressed as copy number per ng of total DNA to control for the variation in total DNA ob-
tained for individual samples.
Statistical analyses
Descriptive statistics for Shannon diversity index [19], a common ecological parameter, are
presented. For ease of interpretation, effective number of taxa (EFT) was calculated from this
index [19]. Comparisons between two groups were performed individually for each taxa using
the two-part test and the negative log p-values are displayed using the Manhattan plot [20].
Principal component analysis was performed on the relative abundance data from each sample.
A small constant (0.01) was added to eliminate zero values prior to the application of the cen-
tered log ratio transformation recommended for compositional data [21, 22]. All analyses were
performed using SAS Version 9.3 software (SAS Institute Inc.: Cary, NC, 2011). Manhattan
plots and summary figures were generated using Explicet [23] (www.explicet.org).
Results
Subject characteristics
Seventy subjects were recruited from Chicago, IL (n = 26) and Aurora, CO (n = 44). Details of
subjects’ demographics, clinical characteristics and ethnic diversity are provided in Table 1.
Some normal subjects and half of the EoE subjects were on PPI, but these were not considered
a treatment for these groups, in accordance with published EoE consensus recommendations
[7–9]. EoE subjects were considered “treated” when histologic remission was demonstrated on
standard of care treatment including topical steroids or dietary restrictions. Treatment for sub-
jects with GERD was prescription of PPI.
Bacterial load but not diversity is increased in EoE
The average bacterial load detected in all subjects with EoE was significantly greater than that
determined from normal subjects (Fig 1A). These differences between disease and normal
states were not influenced by treatment (Fig 1B) or disease activity (Fig 1C). By comparison,
the average bacterial load found in GERD subjects was also significantly increased relative to
normal esophagus control subjects (Fig 1A). No significant differences were observed for alpha
diversity, represented as Effective Number of Taxa across any of the subject groups (Fig 1D).
Effect of inflammation and treatment on esophageal phyla and genera
We next determined the impact of inflammation and treatment on the bacterial composition
in EoE. To accomplish this, we compared the bacterial taxa identified based on subject groups
(Table 1) at the level of phylum and genus. Four phyla (Bacteroidetes, Firmicutes, Fusobacteria
and Proteobacteria) were predominant, and similar, in active EoE, treated EoE and normal mu-
cosa (Fig 2A).
In contrast to EoE, untreated GERD showed an increase in Firmicutes and decrease in Proteo-
bacteria compared to normal subjects. Additionally, treatment of GERD with PPI was associated
Microbiome Shift in Esophagitis
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Table 1. Subject Characterization Summary.
Subject Groups Number of
Subjects
Number of Subjects on PPI (%
of total) or specific treatment
for EoE group
Age Average
years (range in
years)
Male Gender
(% of total)
Ethnicity (%
white)
Collected in
Aurora CO (% of
total)
Eosinophilic
esophagitis–active
(untreated)
11 5 (45.5%) 19.4 (9–49) 9 (82%) 10 (91%) 5 (45.5%)
Eosinophilic
esophagitis–remission
(treated)
26 PPI 12 (46%) Diet 14 (54%)
Steroid 6 (23%) Diet and steroid
6 (23%)
17.1 (7–59) 19 (73%) 24 (92%) 12 (46%)
Gastro-esophageal reflux
disease-active
(untreated)
4 0 (0%) 29.5 (11–53) 1 (25%) 4 (100%) 2 (50%)
Gastro-esophageal reflux
disease-remission
(treated)
4 4 (100%) 13.8 (10–16) 2 (50%) 4 (100%) 4 (100%)
Normal Esophagus 25 11 (44%) 14.2 (11–18) 7 (28%) 19 (79%) 21 (84%)
doi:10.1371/journal.pone.0128346.t001
Fig 1. The esophageal bacterial load is increased in subjects with EoE and GERD: Analysis by 16S Q-PCR. The esophageal bacterial load was
captured using the EST as previously described [5]. A. The copy number of bacteria per ng of DNA is significantly increased in subjects with EoE, and GERD
as compared to Normal. B. Treatments (Trt) do not significantly change the load of bacteria in each disease. C. The disease activity or response to treatment
does not significantly change the load of bacteria in EoE. D. The effective number of taxa is similar in Normal, EoE and GERD. The mean ± SEM are shown.
Normal n = 25, EoE n = 37, GERD n = 8. Mean and SEM, two-sample t-test * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001.
doi:10.1371/journal.pone.0128346.g001
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with an expansion of Proteobacteria. Comparisons of the predominant genera present in the dif-
ferent subject groups showed similar distribution with the exception of PPI treated GERD (Fig
2B). Treatment of GERD produced a community with similar relative abundance among the pre-
dominant taxa observed, without major changes to the genera present. The one exception is
Aggregatibacter that was not detected in untreated GERD but expanded to a relative abundance
of 18% in the PPI treated GERD group with a concomitant decrease of Streptococcus relative
abundance from 47% in untreated GERD to 21% in PPI treated GERD. However, the relative
abundance of Streptococcus was not decreased and Aggregatibacter was not increased in the other
groups (normal and EoE) where half of the subjects were treated with PPI (Table 1) (Fig 2B).
Principal Components Analysis (PCA) focused on EoE subjects alone to examine the rela-
tionship between subjects based on communities present. The first two components are shown
in Fig 3 along with vectors displaying the weight and relationship with the genera that have the
highest contribution to these components. The first two components explain approximately
29% of the variability in the dataset. The EoE subjects are generally positive in PC1 correspond-
ing to larger amounts of Haemophilus, Pasteurella, Fusobacterium and Aggregatibacter and
Fig 2. Esophageal phyla are similar in EoE compared to normal esophagus, and treatment affects the
genus abundance in EoE and GERD. Abundance of esophageal phyla and genera as captured using the
EST. A. Bar graphs present the aggregate of the relative phylum abundance on the ESTs of Normal subjects
(n = 25), EoE subjects untreated (n = 11), treated (n = 26), and GERD subjects untreated (n = 4), PPI treated
(n = 4). Each phylum is indicated in a different color. The width of the bar corresponds to the relative phylum
abundance. B. Bar graphs present the aggregate of the relative genus abundance on the ESTs of Normal
subjects (n = 25), EoE subjects untreated (n = 11), treated (n = 26), and GERD subjects untreated (n = 4),
treated (n = 4). Each genus is indicated in a different color. The width of the bar corresponds to the relative
genus abundance. The Other category includes taxa with <1% relative abundance in all samples.
doi:10.1371/journal.pone.0128346.g002
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smaller amounts of Actinomyces, Veillonella and Rothia. Streptococcus was negatively correlat-
ed with Leptotrichia.
We compared the untreated EoE and normal subjects using a two-part statistic to determine if
any genera differed across these two groups.Haemophiluswas identified as significantly increased
in untreated EoE compared to normal control subjects (p = 0.047, Fig 4 and S1 Table). All subject
groups were positive forHaemophilus, but the relative abundance was significantly higher in un-
treated EoE subjects compared to control subjects with a normal esophagus or GERD (Fig 5).
We also observed a pronounced difference in EoE subjects between centers (Chicago and
Aurora). While the microbiota in control subjects between centers were not significantly differ-
ent (not shown), the comparison of EoE subjects in Chicago and Aurora demonstrated that, ex-
cept for Streptococcus, all significantly different taxa were significantly increased in the Aurora
relative to Chicago group (Fig 6 and S2 Table).
Discussion
Here we report that the inflamed esophagus in EoE contains a significant increase inHaemo-
philus, and that this microbial pattern returns to that found in GERD and subjects with a
Fig 3. Principal Components Analysis (PCA) of Normal and EoE samples. PCA using normal esophagus (n = 25) and EoE samples (n = 11 untreated
and n = 26 treated). The biplot displays the first two principal components which explains 29% of the variability across genera, as well as vectors
corresponding to the weight and direction of the loadings for the highest weighted genera. Vectors pointing in the same direction are genera that are
positively correlated; those going in opposite directions are negatively correlated.
doi:10.1371/journal.pone.0128346.g003
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normal esophagus following standard of care EoE treatment. In addition, we determined that
epithelial eosinophilia did not seem to influence the load of bacteria, and that the microbiome
measured in EoE subjects differed in Chicago and Aurora. Taken together, these results suggest
that different mechanisms may influence the microbiome in EoE compared to that seen in
other conditions, and that the geographical location of a subject and / or treatment may influ-
ence the microbiome in EoE.
Fig 4. Manhattan plot of the two part statistical analysis of normal (n = 25) versus untreated EoE
(n = 11). The plot shows the negative log10 p-value for each taxon identified. The single significant genus
identified wasHaemophilus, which was elevated in EoE subjects.
doi:10.1371/journal.pone.0128346.g004
Fig 5. Comparison ofHaemophilus across all subject groups. The relative abundance of Haemophilus
for each group is plotted. Box represents median and 25th and 75th percentile (interquartile range, IQR) and
whiskers represent 1.5x IQR. Individual samples outside the 1.5x IQR are marked as open circles.
doi:10.1371/journal.pone.0128346.g005
Microbiome Shift in Esophagitis
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The load of bacteria is increased in subjects with EoE and GERD, independent of the diag-
nosis, treatment, or disease activity in subjects with EoE, however the treated subjects may not
be truly uninflamed at the time of sampling (Fig 1). However, the number of taxa and commu-
nity composition was similar across all groups, indicating that increased load is associated with
inflammation. The predominant taxa were similar in EoE subjects irrespective of the type of
treatment, elimination diet or topical corticosteroid. However, subjects with GERD on PPI had
a more consistent distribution of predominant taxa, and emergence of a specific proteobacteria
lineage, Aggregatibacter, with a concomitant decrease in Streptococcus (Firmicutes). These find-
ings are in agreement with a prior study that identified a decrease in Streptococcus in GERD
[24], but the increase in Aggregatibacter in subjects on PPI has not been reported. The effect of
PPI treatment on microbial communities is known for gastric fluids and esophageal tissues
[25]. It has been suggested that PPIs may target certain bacterial proton pumps (P-type
ATPases) typical of Streptococcus spp. PPIs may also affect the esophageal microbiota by in-
creasing the pH of refluxed gastric contents [26]. However, the impact of PPI on Streptococcus
and Aggregatibacter seems to be limited to the GERD group as the relative abundance of these
genera were not changed in the normal or EoE groups.
Fig 6. Manhattan plot of the two part statistical analysis of Aurora, CO (n = 17) versus Chicago, IL (n = 20) microbiome samples. The plot shows the
negative log10 p-value for each taxon identified. There are six significant taxa identified. The peaks correspond to 1. Actinomyces (p = 0.048), 2. Prevotella
(p = 0.016), 3. Streptococcus (p = 0.016), 4. Parvimonas (p = 0.022), 5. Fusobacterium (p = 0.009) and 6. Aggregatibacter (p = 0.027). All significantly
different taxa were elevated in the Aurora relative to Chicago group except for Streptococcus.
doi:10.1371/journal.pone.0128346.g006
Microbiome Shift in Esophagitis
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The primary genus differentially identified in the untreated EoE subjects was Haemophilus,
which contains known human pathogens such asHaemophilus influenzae. It is possible that
the EoE group contains different community types that were not apparent in this analysis. The
PCA analysis suggests that the majority of the variability across microbial compositions is not
directly due to disease state or treatment, as most of the treated EoE subjects were similar in
the first two principal components (Figs 2 and 3). However, there is a significant overlap of a
subset of the subjects undergoing treatment with the untreated group; it is unclear if this repre-
sents differential response to treatment.
The disease activity in the esophagus does not seem to directly affect the load of bacteria in
EoE. However, eosinophils have been described to possess numerous anti-microbial properties
with the release of their granule proteins, defensins, and extracellular DNA traps [2–4]. The
microbiota in untreated EoE subjects showed a shift from a mostly Gram-positive population
(Firmicutes) to an increase in Gram-negative bacteria (primarily Proteobacteria) similar to
what has been described in GERD [24]. Previous implication of Gram-negative bacterial in-
volvement in reflux esophagitis [27] is consistent with the observed increase in Proteobacteria
andHaemophilus in EoE.
These data suggest that treatment may impact the microbiota. Subjects at Children's Hospi-
tal Colorado, in Aurora, CO were treated a combination of topical corticosteroids and/or elimi-
nation diets, whereas subjects in Chicago, IL were treated mostly with food elimination diets.
Diet is known to have an important effect on the lower gastrointestinal microbiota. Studies of
diet-induced changes in the microbiota in the lower gut have shown that diet rapidly alters the
gut microbiome [28–30]. However, the effect of diet on the upper gastrointestinal tract is large-
ly unknown. We examined treatment in the current dataset, but additional subjects are needed
to allow subgroup analysis capable of isolating the multiple approaches to clinical management
of these patients. While corticosteroids and food elimination diets are standards of treatment
in EoE, the current study was not sufficiently powered to inform the effects of individual treat-
ments on the esophageal microbiota. In addition to clinical management, many factors impact
the microbiome in children including the mode of child birth, early feeding methods, and envi-
ronmental exposure [31, 32]. Future studies will require more detailed dietary information for
analysis to better understand its impact on the variability in esophageal bacterial communities
observed in EoE.
As we previously published, the esophageal microbiome detected by the EST is representative
of the mucosal microbiome present on paired mucosal biopsies, and specific to the esophagus,
which is significantly different from the oral and nasal microbiome [5]. However, the capacity
forHaemophilus to enter the epithelial layer suggests that these organisms may be able to exploit
the damaged barrier in EoE to help propagate and perpetuate inflammation in this disease [33,
34]. In the current study, we did not observe any significant differences in the esophageal micro-
biota based on age, gender or ethnicity, but additional studies with a larger number of subjects
will be needed to more fully address these variables. Moreover, the gut microbiome has been
shown to be stable by age 3 [35]. However, based on the cross-sectional design of our study, it re-
mains unclear whether the changes we have identified in the esophageal microbiome contribute
to the pathogenesis of EoE or are a consequence of EoE associated esophageal inflammation and
remodeling. Longitudinal studies will be needed to address this question.
The minimally invasive EST collection approach provides the opportunity to obtain longitu-
dinal samples, which will allow future monitoring of the microbiome during treatment of EoE.
This will provide access for studying changes that occur in conjunction with specific interven-
tions that induce disease remission or exacerbation. The capacity to obtain samples associated
with particular treatments within individual patients will greatly assist our understanding of
their effects by removing the inter-subject variability inherent in the microbiome.
Microbiome Shift in Esophagitis
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This study is the first report to examine the microbiome in esophageal samples from pa-
tients with EoE. An increase in bacterial load was found, but there were limited differences be-
tween the bacterial community composition in treated and untreated EoE. However, patients
with active EoE show a significant increase in Haemophilus in their esophagus. GERD subjects
were included as a disease control, and while the numbers in this group were limited, there was
a strong signal associated with PPI treatment. These data represent a baseline for bacterial
communities in EoE subjects, and provide important findings for design of future studies, e.g.
longitudinal analyses that follow changes in the microbiome during treatment-induced disease
remission. Further studies in multiple centers with a larger number of subjects will help delin-
eate the effect of alterations in the microbiome and treatment on esophageal inflammation,
and potentially help to identify novel therapeutic targets for these diseases.
Supporting Information
S1 Table. Summary of two-part analysis for comparison between untreated EoE and nor-
mal subjects. The number of subjects positive for each taxon, proportion of positive subjects,
and median relative abundance for positive subjects is reported.
(XLSX)
S2 Table. Summary of two-part analysis for comparison between EoE subjects in Aurora
and Chicago. The number of subjects positive for each taxon, proportion of positive subjects,
and median relative abundance for positive subjects is reported.
(XLSX)
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